- Home
- ANY vs LGVN Comparison
ANY vs LGVN Comparison
Compare ANY & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ANY | LGVN |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.9M | 25.9M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ANY | LGVN |
|---|---|---|
| Price | $2.73 | $0.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $30.00 | $3.00 |
| AVG Volume (30 Days) | ★ 6.0M | 186.7K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.76 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,181,000.00 | $709,000.00 |
| Revenue This Year | $15.62 | N/A |
| Revenue Next Year | N/A | $10.81 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.16 | $0.48 |
| 52 Week High | $6.20 | $1.80 |
Technical Indicators
Market Signals| Indicator | ANY | LGVN |
|---|---|---|
| Relative Strength Index (RSI) | 47.49 | 39.45 |
| Support Level | $1.33 | $0.62 |
| Resistance Level | $4.29 | $0.85 |
| Average True Range (ATR) | 0.52 | 0.05 |
| MACD | -0.14 | -0.00 |
| Stochastic Oscillator | 9.76 | 10.04 |
Price Performance
Historical ComparisonAbout ANY Sphere 3D Corp.
Sphere 3D Corp is engaged in the Bitcoin mining business. The company has established an enterprise-scale mining operation through the procurement of mining equipment and partnering with experienced service providers. It generates revenue from mining and selling Bitcoin.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.